Osaka International Cancer Institute

What Osaka International Cancer Institute does

Osaka International Cancer Institute (OICI) is a publicly operated, specialized cancer treatment hospital and research center headquartered in Chuo-ku, Osaka, Japan. Operated as a local independent administrative corporation under the Osaka Prefectural Hospital Organization, OICI traces its origins to the 1962 Osaka Prefectural Adult Disease Center and was rebranded at its current Otemae campus in March 2017. The institute functions as a Designated Functional Hospital, Prefectural Cancer Treatment Coordination Hub, and Cancer Genome Medical Hub Hospital for the Osaka prefecture, delivering comprehensive cancer care across more than 20 specialty departments spanning surgery, chemotherapy, radiation oncology, immunotherapy, genomic medicine, hematopoietic stem cell transplantation (including CAR-T since 2021), and palliative care. Its technology stack includes four da Vinci surgical systems (Xi plus the single-port SP introduced June 2026), 3T MRI, 320-row CT, semiconductor PET-CT, IMRT/VMAT, stereotactic radiosurgery, SBRT, brachytherapy, NBI/AFI endoscopy, and a proprietary pancreatic ultrasound screening system with 13,500+ examinations since 1998.

OICI's business model is anchored in Japan's universal national health insurance under the DPC/fee-for-service hybrid (DPC institutional coefficient 1.5727 as of March 2025), supplemented by uninsured private room fees (¥16,500–60,500/day), first-visit and revisit fees (¥11,000 and ¥3,300), and a ¥300M FY2023–2027 charitable fundraising campaign for equipment renewal. Patients enter primarily through referrals from regional medical institutions via the Quick-In Outpatient booking pathway, with secondary direct access through cancer screening (Human Dock) programs and an online second opinion service. FY2025 operational indicators include 88.8% bed utilization, 7.9-day average length of stay, 1,976 external-beam radiation cases, 1,933 PET-CT scans, 684 breast surgeries, 324 bone/soft tissue tumor surgeries, and 102 hematopoietic cell transplants/CAR-T cases. Co-located research infrastructure — the Cancer Research Institute, Clinical Research Center, Next-Generation Cancer Treatment Development Center, and the Osaka Foundation for Cancer Prevention — along with the Osaka Prefecture Cancer Registry (continuous since 1962) and the Cancer Cell Port biobank, enable integration of clinical care, population-level epidemiology, and translational research.

Name

Osaka International Cancer Institute

Legal name

Osaka International Cancer Institute (大阪国際がんセンター)

Website

https://oici.jp

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Osaka International Cancer Institute is a public specialized cancer hospital and research center operated by the Osaka Prefectural Hospital Organization, delivering comprehensive oncology care — surgery, chemotherapy, radiation, genomic medicine, and transplantation — across more than 20 specialty departments to referred patients throughout the Osaka and Kansai region.

Ownership category

akta.pro rank

Product category

Cancer Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Surgical Oncology (HLAKAFAG), Medical Oncology (HLAKAFAB), Digestive Oncology (GI Cancer Care) (HLAKAEAF), Thoracic (Lung) Oncology (HLAKAFAL), Urologic Oncology (HLAKAOAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Cancer treatment services
• Oncology hospital care
• Radiation therapy services
• Robotic cancer surgery
• Cancer genomic medicine

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical service fees (Health Insurance): As a public medical institution (地方独立行政法人), the center generates revenue primarily through health insurance-covered medical services including consultations, diagnostic procedures, surgeries, chemotherapy, radiation therapy, hospitalizations, and examinations. Revenue is collected through national health insurance billing (DPC/Per-diem payment system combined with fee-for-service for certain items). The center is classified as a DPC-embedded hospital (DPC対象病院) with an institutional coefficient of 1.5727.
2. Donations and charitable contributions: The center accepts monetary and in-kind donations from individuals and organizations. A 300 million yen fundraising goal was set for the FY2023-2027 period for advanced medical equipment renewal. Cumulative donations received by March 2026 were 45,476,156 yen. Donation methods include cash, book drives (古本募金), Amazon wish lists, and bequests.
3. Out-of-pocket and premium services: Revenue from uninsured services including private rooms (特別室) priced at 16,500-60,500 yen per day, first-visit fees of 11,000 yen for general medicine and dentistry, revisit fees of 3,300 yen, and fees for medical certificates and document issuance. Long-term hospitalization fees apply after 180 days at 2,838 yen/day.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

Osaka International Cancer Institute is a specialized cancer hospital providing comprehensive cancer care including diagnosis, surgery, chemotherapy, radiation therapy, immunotherapy, genomic medicine, endoscopic treatment, robotic surgery, hematopoietic stem cell transplantation, and palliative care. The institute also conducts oncology research, clinical trials, cancer screening programs, and maintains the Osaka Prefecture Cancer Registry, serving as a Designated Functional Hospital, Prefectural Cancer Treatment Coordination Hub, and Cancer Genome Medical Hub for the Osaka region.

Product overview

Osaka International Cancer Institute (OICI) is a specialized cancer hospital offering comprehensive cancer care through multiple treatment modalities. The institution operates as a single unified hospital with specialized departments for different cancer types, including digestive medicine, respiratory medicine, hematology, breast surgery, gynecological oncology, urology, neurosurgery, radiation oncology, and palliative care. Core offerings include robotic surgery using da Vinci systems, advanced diagnostic imaging (PET-CT, MRI, CT), radiation therapy (IMRT, SBRT, brachytherapy), chemotherapy and molecular targeted therapy, cancer genomic medicine, stem cell transplantation, CAR-T therapy, and comprehensive cancer screening programs. The institute also provides supportive services including second opinion consultations, palliative care, and rehabilitation. Treatment is organized by cancer type with specialized centers for gastric, lung, breast, pancreatic, rectal, rare cancers, and robotic surgery.

Differentiator

Problem solved

Functional benefit

Products and services

• Robot-assisted Surgery (da Vinci Surgical System) Robotic surgery using the da Vinci Xi and da Vinci SP surgical systems for various cancer types including urological, gynecological, digestive, and thoracic surgeries, offering minimally invasive procedures with enhanced precision.
• Radiation Oncology Services Comprehensive radiation therapy including IMRT/VMAT, stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), brachytherapy, and combined chemoradiotherapy for various cancer types.
• Hepatobiliary and Pancreatic Cancer Treatment Specialized treatment for liver, gallbladder, bile duct, and pancreatic cancers including radiofrequency ablation (RFA), microwave ablation, TACE, systemic therapy, and proprietary pancreatic precision ultrasound screening.
• Hematology and Blood Cancer Treatment Treatment for leukemia, malignant lymphoma, multiple myeloma, and other hematologic malignancies including hematopoietic stem cell transplantation (allogeneic, autologous, cord blood, HLA half-match) and CAR-T cell therapy.
• Respiratory Medicine and Lung Cancer Treatment Diagnosis and treatment of lung cancer and thoracic malignancies using bronchoscopy, EBUS-TBNA, biopsy, molecular targeted therapy, and biomarker-driven treatment.
• Cancer Genomic Medicine / Gene Panel Testing Comprehensive genomic profiling for solid tumors and blood cancers to guide personalized treatment decisions, including cancer gene panel testing (NCC_ONCOPANEL, HemeSight) and genomic counseling.
• Breast Cancer Treatment and Breast Reconstruction Comprehensive breast cancer treatment including surgery, chemotherapy, hormone therapy, and oncoplasty breast reconstruction surgery with approximately 60% breast-conserving outcomes.
• Diagnostic Imaging Services Advanced diagnostic imaging including PET-CT (GE Discovery MI), 3T MRI (Magnetom Prisma), 320-row CT (Aquilion One), mammography, ultrasound, and nuclear medicine imaging for cancer diagnosis and staging.
• Cancer Screening and Health Checkup (Human Dock) Comprehensive cancer screening and health examination programs including 2-night/3-day and 1-night/2-day inpatient cancer-specific screening and cardiovascular disease screening.
• Second Opinion Consultation Second opinion consultations for cancer patients seeking additional medical perspectives on diagnosis and treatment options, including online consultations and international medical institution-based second opinions.
• Palliative Care Services Supportive and palliative care for cancer patients focusing on symptom management, pain relief, psycho-oncology, nutritional therapy, and quality of life improvement.
• Donation Program for Advanced Medical Equipment Charitable donation program supporting advanced medical equipment, research, and staff education, with a 300 million yen target goal for the FY2023-2027 period.

Quantifiable outcome

• 88.8% bed utilization rate in FY2025 with average hospital stay of 7.9 days
• +12 more outcomes

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature18 records

Partnerships

13 partnerships are on record, tiered core and minor.

• 大阪大学 (Osaka University)coreStrategic or Co-development Partner · 1 January 2017OICI maintains deep academic-clinical integration with Osaka University, with numerous physicians holding concurrent positions at Osaka University School of Medicine. Joint research in cancer treatment, genomic medicine, and stem cell transplantation. Medical staff include Osaka University clinical professors and visiting professors. Partnership enables bench-to-bedside translation of research discoveries.
• 大阪重粒子線センター (Osaka Heavy Particle Medical Center)coreStrategic or Co-development PartnerAdjacent facility offering heavy particle (carbon ion) radiation therapy. OICI physicians participate in treatment planning and management for patients referred for heavy particle therapy. Collaboration enables access to cutting-edge particle beam treatment for appropriate cases including lung cancer and sarcoma.
• 大手前病院 (Otemae Hospital)minorStrategic or Co-development PartnerRegional cardiovascular surgery partner within the Osaka prefectural medical network. Cancer patients with concurrent cardiovascular conditions may be referred for surgical treatment.
• 大阪医療センター (Osaka Medical Center)minorStrategic or Co-development PartnerRegional partner hospital for cardiac surgery referrals within the Osaka prefectural medical network.
• 森之宮病院 (Morinomiya Hospital)minorStrategic or Co-development PartnerRegional partner hospital within the Osaka prefectural medical network for referral of complex cases requiring specialized cardiac and vascular treatment.
• 大阪成人病予防協会 (Osaka Foundation for Cancer Prevention and Adult Diseases)coreStrategic or Co-development PartnerCo-located on the 5th floor of OICI. Jointly operates cancer screening and prevention programs, leveraging OICI's clinical expertise in cancer treatment with the association's preventive health mission.
• 大阪府 (Osaka Prefecture)coreStrategic or Co-development PartnerOICI collaborates with Osaka Prefecture to develop and implement the Osaka Prefecture Cancer Countermeasure Promotion Plan (大阪府がん対策推進計画), based on the Osaka Prefecture Cancer Registry (continuous since 1962). The hospital serves as the core institution for cancer care delivery and policy implementation across the prefecture.
• 大阪府立病院機構 (Osaka Prefectural Hospital Organization)coreStrategic or Co-development PartnerOICI is operated by the Osaka Prefectural Hospital Organization (地方独立行政法人大阪府立病院機構), a public medical corporation managing multiple hospitals in Osaka prefecture. The organization provides administrative and governance oversight. Received 紺綬褒章 designation in 2024 for charitable contributions.
• 大阪南医療センター (Osaka Minami Medical Center)minorStrategic or Co-development PartnerOICI and Osaka Minami Medical Center have been designated as a hospital group (グループ指定), enabling coordinated cancer care delivery and patient sharing between the two facilities.
• 地方独立行政法人大阪府立病院機構 (Osaka Prefectural Hospital Organization)coreStrategic or Co-development PartnerParent public medical corporation operating OICI,大阪南医療センター, and other prefectural hospitals. Provides governance, management oversight, and centralized administrative functions across the hospital network.
• 大阪工業大学 (Osaka University of Science and Technology)minorStrategic or Co-development PartnerAcademic partnership for joint research. OICI's blood medicine department collaborates with the university on advanced research topics including mitochondrial transplantation and novel gene discovery.
• 国Ahead国立がん研究センター東病院 (National Cancer Center Hospital East)coreStrategic or Co-development PartnerOICI actively participates in LC-SCRUM-Asia, an Asia-wide genomic screening project led by NCCHE for lung cancer. Joint research on rare genetic mutations enables patient access to targeted therapies and clinical trials.
• 大阪湾岸岸医療連携ネットワーク (Osaka Bay Area Medical Coordination Network)minorChannel Partner/ Reseller/ DistributorA regional medical coordination network within the Osaka Bay area facilitating multi-institutional collaboration for cancer diagnosis and treatment, enabling OICI to serve as the tertiary care hub while community hospitals manage ongoing care.

Scale indicators18 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Cancer Institute Hospital of JFCR: Tokyo-based cancer specialty hospital operated by the Japanese Foundation for Cancer Research. Comparable as a Japanese cancer-only hospital offering multidisciplinary oncology care, advanced surgery, and clinical research.
• National Cancer Center Japan: Japan's premier national cancer hospital with locations in Tokyo (Central) and Kashiwa (East). Directly comparable as a government-designated cancer specialty hospital offering comprehensive oncology services, genomic medicine, and clinical trials at the national level.

Others

• Osaka University Hospital: Academic general hospital with strong oncology presence and OICI's primary academic partner. Comparable through deep clinical-research integration, oncology faculty overlap, and joint clinical trial activity with OICI.

Regional players

• Seoul National University Cancer Hospital: South Korea's leading cancer specialty hospital affiliated with Seoul National University. Comparable as an academic comprehensive cancer center offering robotic surgery, genomic medicine, and clinical trials in the broader Asian market.
• National University Hospital (Singapore) - NCIS: Singapore's National University Cancer Institute offering comprehensive cancer care. Comparable as an academic regional cancer center with advanced therapies, clinical trials, and a regional referral base in Southeast Asia.

Broad incumbents

• Gustave Roussy Institute: Leading European cancer center located near Paris, France. Comparable as a comprehensive cancer hospital and research center offering all major oncology specialties, advanced therapies, and clinical trials across tumor types.
• Christie NHS Foundation Trust: Largest single-site cancer center in Europe located in Manchester, UK. Comparable as a comprehensive cancer specialty hospital offering advanced radiation therapy, surgical oncology, hematology/ transplantation, and clinical trials within a public health system framework similar to Japan's structure.
• MD Anderson Cancer Center: World-leading US cancer specialty hospital and research center. Comparable as a comprehensive cancer center offering multidisciplinary oncology care, genomic medicine, robotic surgery, and an extensive clinical trial portfolio.
• Memorial Sloan Kettering Cancer Center: Premier US cancer specialty hospital. Comparable in offering comprehensive cancer care across all major tumor types with leading surgical, medical oncology, and radiation therapy programs plus robust clinical research.
• Princess Margaret Cancer Centre: Canada's largest cancer treatment and research center, affiliated with University Health Network. Comparable as a comprehensive academic cancer center offering multidisciplinary care, advanced radiation therapy, and genomic medicine.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/大阪府立成人病センター-412926952217181
• Instagraminstagram.com/oici_1181

Revenue estimate

Valuation estimate

Number of profiles

Profiles29 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osaka International Cancer Institute